A high frequency of MDM2 gene amplifications leading to overexpression has been identified in a variety of tumor types, including breast carcinomas [49], glioblastomas [50], B cell lymphomas [51], and myeloid neoplasms [52]. This evidence concerns the gene MDM2 and neoplasm.